CN108567799A - A kind of full caprophyl complex capsule and its preparation method and application - Google Patents
A kind of full caprophyl complex capsule and its preparation method and application Download PDFInfo
- Publication number
- CN108567799A CN108567799A CN201810865338.1A CN201810865338A CN108567799A CN 108567799 A CN108567799 A CN 108567799A CN 201810865338 A CN201810865338 A CN 201810865338A CN 108567799 A CN108567799 A CN 108567799A
- Authority
- CN
- China
- Prior art keywords
- full
- caprophyl
- capsule
- complex capsule
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
The present invention relates to drug fields, provide a kind of full caprophyl complex capsule, including wall material and core material, and the wall material is enteric capsule shell, and the core material includes full caprophyl and prebiotics；Living bacteria count in the full caprophyl complex capsule is 1 × 1010~2.88 × 1010A/grain.The present invention is using full caprophyl and prebiotics as core material, the characteristic of beneficial microbe growth and breeding is selectively promoted using prebiotics, significantly improve the profitable strain quantity in full caprophyl, reduce pathogenic flora quantity, on the one hand it can improve and have the effective beneficial microbe time-to-live in full caprophyl, on the other hand function and effect of the full caprophyl complex capsule of the present invention after intestinal colonisation can also be improved, intractable Clestridium difficile is infected, constipation, diarrhea, Crohn disease, ulcerative colitis, the patients such as irritable bowel syndrome and Food intolerance have significant curative effect.
Description
Technical field
The present invention relates to drug fields, and in particular to a kind of full caprophyl complex capsule and its preparation method and application.
Background technology
The enteric microorganism ecosystem is most complicated and maximum microecosystem in the mammalian body.However, big now
Generally using for amount antibiotic and changing so that very big change has occurred in the composition of human intestinal microorganisms, just for dietary structure
Normal intestinal flora is destroyed, or even develops into clostridium difficile infection, and consequently leads to the generation of some new diseases.
" caprophyl transplanting " (Fecal microbiota transplantation, FMT) refers to, will be in healthy human faecal mass
Functional flora is transplanted in patient's gastrointestinal tract, and new intestinal flora is rebuild, and realizes the treatment of enteron aisle and parenterally disease.Caprophyl
Transplant the crucial salvage treatment as refractory inflammatory bowel disease (Crohn disease, ulcerative colitis), the good effect played
Fruit.
China has 1700 as long as with the history of caprophyl porting principle treatment disease, between 300 years to 400 years Christian era,
Ge Hong《Handbook of Prescriptions for Emergencies》It records " one liter of drink excrement juice, i.e., living ", i.e., user's excrement treats clearly food poisoning, diarrhea, fever, dying
Patient.《Compendium of Materia Medica》In the also treatment of useful human faecal mass severe diarrhea and food poisoning content.
In modern medicine history, the transplanting of earliest caprophyl is reported in 1958, and American surgeon Eiseman etc. is to by golden yellow
4 patients of the serious pseudomembranous enteritis caused by color staphy lococcus infection implement excrement transplanting.1981, Bowden etc. was using warp
The method that small intestine sets pipe input liquid manure cures 16 pseudomembranous enteritis patients.Nineteen eighty-three, Sweden Schwan etc. use excrement bacterium solution
To recurrent intractable Clestridium difficile, infection (CDI) patient carries out rectum bowel lavage.2013, caprophyl transplantation treatment side
Case is put into the clinical guidelines of U.S. Patent recurrent CDI.
What is used due to caprophyl transplanting is viable bacteria, and caprophyl, which needs to be transplanted to specific disease sites, is bred, ability
Enough play the effect for the treatment of intestines problem.It is in laboratory by Modern Scientific Instruments in Chinese people currently, standardize the transplanting of full caprophyl
Property detach and obtain highly purified flora, then the bacterium solution of quantization is infused into patient's enteral through scope or drainage tube.
Caprophyl transplanting mode includes mainly entirely：Nasogastric tube, Nasal cavity intestinal tube, superior gastrointestinal endoscope (gastroscope), Sigmoidoscope set pipe
Or retention enema.The shortcomings that these full caprophyl transplanting modes is to require high, complicated for operation, inconvenient, patient to operating technology
Pain is not easily accepted by, influences that daily life quality, administration time are long, and cannot be guaranteed the profitable strain in the full caprophyl after transplanting
Growth and activity occupy advantage in receptor enteron aisle.Therefore, these full caprophyl transplantation methods and without become routine treatment
Foreground.
Caprophyl liquid is wrapped up with excrement Tiny ecosystem capsulae enterosolubilis currently, existing in existing research, the micro- life of excrement made of this mode
State bilayer capsulae enterosolubilis uses glycerine as protective agent, after not glycerinated excrement Tiny ecosystem capsulae enterosolubilis preserves 72h at -80 DEG C
Living bacteria count will significantly reduce, and the holding time is short, and (Yan Chen, Cao Hailong, dream sparrow, waits the system of excrement Tiny ecosystem capsulae enterosolubilis perhaps
Standby and its quality control [J] China digests magazine, 2016,36 (6):407-411.).In order to protect and maintain in caprophyl capsule
Profitable strain quantity, it is existing research to preparing caprophyl when freeze drying protectant, lyophilisation condition be optimized, such as China specially
Sharp CN104922158A, but it is primarily to promote the damaed cordition that is lyophilized in the preparation of caprophyl, and be not known and how to prolong
The holding time of long caprophyl capsule.
Invention content
The present invention carries to solve the problems, such as that the full caprophyl capsule holding time is short in the prior art, field planting effect is inapparent
A kind of full caprophyl complex capsule is supplied, the holding time is longer, profitable strain content dramatically increases, and the function and effect after transplanting are good.
To solve the above-mentioned problems, the present invention provides following technical schemes：
The present invention provides a kind of full caprophyl complex capsule, including wall material and core material, the wall material is enteric capsule shell, institute
It includes full caprophyl and prebiotics to state core material；Living bacteria count in the full caprophyl complex capsule is 1 × 1010~2.88 × 1010
A/grain.
Preferably, the enteric capsule shell is selected from small intestine enteric capsule shell or colon enteric capsule shell.
Preferably, the mass ratio of the full caprophyl and prebiotics is 5~10:2~5.
Preferably, the preparation method of the full caprophyl includes the following steps：
(1) excrement is impregnated with 3~5 DEG C of sterile saline, is filtered after stirring, it is excrement to take filtrate, collection liquid phase component
Just filtrate；
(2) filtrate of dejecta for obtaining step (1) is centrifuged with the rotating speed of 1500~3000r/min, takes precipitation and sterile life
Brine mixing is managed, full caprophyl is obtained.
Preferably, in the step (1), the filtering uses the strainer of aperture 2mm, 1mm, 0.5mm and 0.25mm successively
Filtering.
Preferably, in the step (1), the ratio of stool quality and sterile saline volume is 1g:300~800ml；
In the step (2), the ratio of the precipitation quality and sterile saline volume is 1:5~15.
Preferably, the prebiotics include stachyose, galactooligosaccharide Oligomeric manna sugar and one kind in xylo-oligosaccharide or
It is a variety of.
The present invention also provides the preparation methods of full caprophyl complex capsule described in above-mentioned technical proposal, include the following steps：
Full caprophyl and prebiotics are mixed, freeze-drying obtains core material；Core material is distributed into enteric capsule shell, is obtained
Full caprophyl complex capsule.
Preferably, the condition of the freeze-drying is：Temperature -50~-53 DEG C are freeze-dried, sublimation drying is for 24 hours
Within.
The present invention also provides full caprophyl complex capsules described in preceding solution in preparing full caprophyl transplanting preparation
Using.
Compared with prior art, technical solution provided by the invention has the following advantages：
The present invention provides a kind of full caprophyl complex capsule, including wall material and core material, the wall material is enteric capsule shell, institute
It includes full caprophyl and prebiotics to state core material；Living bacteria count in the full caprophyl complex capsule is 1 × 1010~2.88 × 1010
A/grain.The present invention selectively promotes beneficial microbe growth and breeding using full caprophyl and prebiotics as core material using prebiotics
Characteristic significantly improves the profitable strain quantity in full caprophyl, reduces pathogenic flora quantity, on the one hand can improve and have in full caprophyl
On the other hand the effective beneficial microbe time-to-live, it is fixed in enteron aisle can also to improve full caprophyl complex capsule of the present invention
Function and effect after plant, for intractable Clestridium difficile infection, constipation, diarrhea, Crohn disease, ulcerative colitis
Inflammation, irritable bowel syndrome, Food intolerance, autoimmune disease, chronic fatigue syndrome, self-closing disease, obesity, diabetes,
The patients such as asthma, atopic dermatitis, eczema and Alzheimer's disease have significant curative effect.
Full caprophyl contained by full caprophyl complex capsule provided by the invention is viable bacteria, and the mode of oral medication being capable of effectively letter
Change full caprophyl field planting operation；Using enteric capsule shell as wall material, the lesion locations that can be accurately located in enteron aisle discharge full excrement
Bacterium can also improve the acceptance of patient.
Description of the drawings
Fig. 1 is pair for the front and back Food intolerance index of correlation that obese people takes orally full caprophyl complex capsule in embodiment 4
Than figure (n=15)；
Fig. 2 is that obese people takes orally the irritable bowel syndrome IBS scale scores before and after full caprophyl complex capsule in embodiment 4
Comparison diagram (n=15)；
Fig. 3 is the comparison diagram (n that obese people takes orally the mental scale scoring before and after full caprophyl complex capsule in embodiment 4
=15)；
Fig. 4 is that obese people takes orally the difference flora before and after full caprophyl complex capsule and the pass with donor in embodiment 4
System.
Specific implementation mode
The present invention provides a kind of full caprophyl complex capsule, including wall material and core material, the wall material is enteric capsule shell, institute
It includes full caprophyl and prebiotics to state core material；Living bacteria count in the full caprophyl complex capsule is 1 × 1010~2.88 × 1010
A/grain.
The full caprophyl complex capsule term of validity provided by the invention is 30d, during this period the full caprophyl bioactivity in capsule
It will not significantly change.
In the present invention, the capsulae enterosolubilis is preferably selected from small intestine capsulae enterosolubilis or colon capsulae enterosolubilis, according to illness
The difference at position can select specific type.Capsulae enterosolubilis can effectively resist the decomposition of gastric juice, under the conditions of gut pH
It just can largely discharge active principle.Thus using enteric capsule shell as wall material can effective protection full caprophyl arrival enteron aisle, subtract
Few full caprophyl loss, and then realize and be administered by oral route.
The present invention is not particularly limited the composition of the capsulae enterosolubilis and source, using the capsulae enterosolubilis for meeting standards of pharmacopoeia
Shell.
In the present invention, when the capsulae enterosolubilis is selected as small intestine capsulae enterosolubilis, the capsule shells are 6~7 in pH value
In the range of dissolve, do not discharge active principle substantially in (gastric juice) under acidic environment.The pH value of small intestine in the range of 6~7,
After taking orally full caprophyl complex capsule of the present invention, when capsule is moved to small intestine site, capsule shells are dissolved, in capsule
Full caprophyl positioning is released to small intestine, completes full caprophyl transplanting, and full caprophyl is bred and played bioactivity in small enteral, reaches
The purpose of reconstruction patients intestinal microflora.Meanwhile contained prebiotics are also released in full caprophyl complex capsule of the present invention
It is put into small intestine, adequate nutrients can be provided for the full caprophyl of transplanting, prevent beneficial microbe by adverse circumstances in Intestinal Mucosal Injury in Patients Undergoing
It influences and fails.
In the present invention, when the capsulae enterosolubilis is selected as colon capsulae enterosolubilis, the capsule shells are 7~8 in pH value
In the range of dissolve, do not discharge active principle substantially in (gastric juice) under acidic environment.Full caprophyl complex capsule of the present invention
Performance in colon is same as above, and details are not described herein.
In the present invention, in the core material, the mass ratio of full caprophyl and prebiotics is preferably 5~10:2~5, more preferably
6~8:3~4.In full caprophyl complex capsule of the present invention, core material content is determined according to the viable count of complete every gram of caprophyl.
In the present invention, the prebiotics primarily serve the effect for stimulating the proliferation of the profitable strain in full caprophyl, and energy
It enough improves the pot-life of full caprophyl complex capsule, that is, maintains and improve effective viable bacteria of full caprophyl in full caprophyl complex capsule
Number.The full caprophyl and prebiotics mass ratio limited according to the present invention is compounded, and can be significantly improved in full caprophyl beneficial to micro- life
The quantity of object, and the term of validity of full caprophyl complex capsule is extended into 30d or so.The additive amount of the prebiotics is less than this hair
The bright range can not then play the role of effectively facilitating beneficial microbe growth and maintain full caprophyl living bacteria count；It is prebiotic
It is unbalance that the additive amount of member higher than range of the present invention is then easy to cause full caprophyl flora, also can not after field planting in Intestinal Mucosal Injury in Patients Undergoing
Play effective therapeutic effect.
In the present invention, the full caprophyl is preferably prepared as follows to obtain：
(1) excrement is impregnated with 3~5 DEG C of sterile saline, is filtered after stirring, take filtrate, obtains filtrate of dejecta；
(2) filtrate of dejecta for obtaining step (1) is centrifuged with the rotating speed of 1500~3000r/min, takes precipitation and sterile life
Brine mixing is managed, full caprophyl is obtained.
In the present invention, the excrement derives from the in vitro excrement of healthy donors, and the criterion of the healthy donors is such as
Under：
(1) donor is selected into standard：
A1, age 18~23 years old, health, unmarried men and women；
A2, rule of life, no bad habit；
A3, antibiotic-free application history in three months；
A4, without enterogastric diseases；
A5, serology and the inspection of excrement infectious agent and culture are feminine gender；
A6, intestinal flora type and diversity are good：It is judged as after high-throughput intestinal flora 16s rDNA genetic tests, benefit
Raw strain class and the diversity of flora are good.
(2) donor exclusion criteria：
B1, drug administration history：Antibiotic, cathartic, slimming drugs were used in three months or are being taken immunosuppressor, changed
Treat drug person；
B2, viruses contact history：Once or in the recent period it is exposed to inhibition of HIV, hepatitis A virus, hepatitis B, hepatitis C virus person；
B3, history of disease：Psychotic disorder, pernicious obesity, constipation, diabetes, inflammatory bowel disease, allergy, metabolic syndrome,
Hypoimmunity, autoimmune disease, enteron aisle relevant disease, chronic fatigue syndrome, digestive system history of operation, gastrointestinal tract are disliked
Property tumour or polyp person, atopic diseases, such as eczema, asthma and gastrointestinal tract eosinophil related disorders；
B4, virology and aetology：
Serologic detection goes out human immunodeficiency virus (HIV), human T-cell virus (HTLV), hepatitis A virus
(HAV), hepatitis B (HBV), hepatitis C virus (HCV), cytomegalovirus, Epstein-Barr virus (EBV), syphilis, quasi-colubriformis and A meter
Bar protozoon etc.；
Fecal sample detects that helicobacter pylori, Yersinia, campylobacter, Shigella, Salmonella, intestines are pathogenic
Escherichia coli, rotavirus, adenovirus, astrovirus, toxoplasma and giardia lamblia etc.；
B5, there are high risk behavior history, drug abuse or forbidden drugs using history, has imprisonment history in the recent period or has epidemic-stricken area trip in the recent period
Swim history.
Meet the full terms that above-mentioned donor is selected into standard, and there is no the people of any one in donor exclusion criteria
Class is judged as healthy donors.
In the present invention, the isolated time of the in vitro excrement is preferably no more than 1h, perhaps even less than 0.5h.
The enterobacteriaceae that full caprophyl transplanting is mainly destroyed using the normal the gut flora structure of healthy population conditioning patient
Group structure, thus intestinal flora normally full excrement can accurately be searched out using healthy donors criterion provided by the invention
Bacterium raw material obtains and has medicative full caprophyl flora for intestinal disorder.
The present invention is not particularly limited the full caprophyl composition in the excrement, selects the in vitro of healthy donors of the present invention
Excrement.
The present invention by providing the diet modification of in vitro excrement the last week, can effectively avoid the high sugar of healthy donors intake,
High in fat and irritable food so as in vitro excrement in full caprophyl Bacterial community it is more reasonable, improve institute of the present invention
State the therapeutic effect of full caprophyl complex capsule.
After obtaining excrement, the present invention impregnates 1~2min of excrement with 3~5 DEG C of sterile saline, and rear agitation and filtration takes
Filtrate obtains filtrate of dejecta.
In the present invention, the purpose for impregnating excrement using the sterile saline of low temperature (3~5 DEG C) is in order at low temperature
Keep bacterial activity in excrement.Currently preferred, the ratio between the quality of the excrement and the volume of sterile saline is
1g:300~800ml, more preferably 1g:400~600ml.
The present invention is stirred the mixture of excrement and sterile saline after immersion, it is made to be uniformly mixed.
In the present invention, the mixing time is preferably 1~2min.The present invention is not particularly limited the agitating mode of the stirring, adopts
With agitating mode mixing known in the art.
In the present invention, the filtering after the stirring is to remove the residue and large particulate matter in excrement.In order into
One step promotes filter effect, currently preferred to be carried out by the way of filtering step by step.When using filtering step by step, the present invention is excellent
The strainer filtering for using aperture 2mm, 1mm, 0.5mm and 0.25mm successively of choosing, the filtrate for taking last time to filter, as full excrement
Bacterium filtrate.
After obtaining full caprophyl filtrate, the present invention centrifuges full caprophyl filtrate with the rotating speed of 1500~3000r/min, centrifuges
To precipitation be resuspended with sterile saline, to obtain full caprophyl.
In full caprophyl preparation method of the present invention, it is dipped to centrifugation from full caprophyl and is resuspended with sterile saline
The process used time preferably be no more than 40min, more preferably 20~30min, to keep the stability and activity of full caprophyl flora.
In the present invention, the centrifugal rotational speed is preferably 2000~2500r/min.In the present invention, the centrifugation time
Preferably 3~5min, more preferably 4min.Under centrifugal rotational speed of the present invention, the microorganism in full caprophyl filtrate is sunk
Drop realizes the separation of full caprophyl flora and water-soluble substances in excrement, full caprophyl is further purified.
The present invention is in order to further increase purification effect, preferably by the way of repeatedly centrifuging.Specifically, the present invention is excellent
Choosing centrifuges full caprophyl filtrate 2~4 times, and the last time is centrifuged gained precipitation from centrifuging second mixes with sterile saline
It closes, 3~5min is centrifuged with the rotating speed of 1500~3000r/min, takes the precipitation sterile saline for centrifuging obtain for the last time
It is resuspended, obtains full caprophyl.
In the present invention, when the multiple centrifugation, the body of quality and sterile saline that last time centrifugation gained precipitates
Product is than preferably 1:4~8, more preferably 1:5~7.
In the present invention, when the resuspension, the volume of obtained precipitation quality and sterile saline is centrifuged for the last time
The ratio between preferably 1:5~15, more preferably 1:8~12.
The full caprophyl Bacterial community that the method is prepared through the invention is reasonable, and beneficial microbe is largely retained,
Activity and stability are good.In the present invention, living bacteria count is 6.8 × 10 in the full caprophyl flora that the above method is prepared10
A/g or more, more preferably 19.6~32.4 × 1010A/g.
In the present invention, the prebiotics include preferably stachyose, galactooligosaccharide, Oligomeric manna sugar and xylo-oligosaccharide
In it is one or more；It is furthermore preferred that the prebiotics include at least stachyose and galactooligosaccharide both.Stachyose with it is low
Prebiotics characteristic can be significantly improved after poly- galactolipin compounding, after stachyose and oligosaccharide galactolipin, Oligomeric manna sugar compounding
Raising prebiotic effect that can be more further, that is, improve that prebiotics are related to promote profitable strain to grow, maintain and enhance full excrement
The active effect of bacterium.
In the present invention, when the prebiotics include preferably stachyose and galactooligosaccharide, the mass ratio of the two is excellent
It is selected as 1:10~10:1.It is furthermore preferred that the prebiotics further include Oligomeric manna sugar, the stachyose and the Oligomeric manna sugar
Mass ratio be preferably 1:5~5:1.
The present invention is not particularly limited the preparation method of the prebiotics, using means known in the art, such as directly
Connect mixing.
Experiments have shown that full caprophyl complex capsule provided by the invention and the full caprophyl capsulae enterosolubilis phase for not containing prebiotics
Than the profitable strains content such as Bifidobacterium, Clostridium leptum, Ackermam Salmonella and Bacillus acidi lactici in full caprophyl flora significantly rises
Height, the principal causatives flora contents such as clostridium, haemophilus and thermophilic courage bacterium in full caprophyl flora significantly reduce.Show the present invention
Full caprophyl structure is more reasonable in the full caprophyl complex capsule provided, is transplanted to the therapeutic effect after Intestinal Mucosal Injury in Patients Undergoing more preferably.
Experiments have shown that full caprophyl complex capsule provided by the invention can be effectively improved the Food intolerance phase of obese people
Close index, the irritable bowel syndrome IBS scale scores for reducing obese people, the anxiety and depression scores, fertilizer for reducing obese people
Cud bacterium abundance in fat crowd significantly rises, that is, shows that full caprophyl complex capsule provided by the invention distinguishes intractable difficulty
Clostridial infection, constipation, diarrhea, Crohn disease, ulcerative colitis, irritable bowel syndrome, Food intolerance, itself
Immunity disease, chronic fatigue syndrome, self-closing disease, obesity, diabetes, asthma, atopic dermatitis, eczema and alzheimer '
Silent disease has significant curative effect.
The present invention also provides the preparation method of full caprophyl complex capsule described in above-mentioned technical proposal, by full caprophyl and prebiotic
Member mixing, freeze-drying obtain core material；Core material is distributed into enteric capsule shell, full caprophyl complex capsule is obtained.
In the present invention, to the mixture of full caprophyl and prebiotics carry out freeze-drying be in order to remove moisture therein,
And improve the stability of full caprophyl.It is dry that freezing is carried out in preparation method of the present invention, after full caprophyl and prebiotics mixing
Dry, prebiotics can also play the role of freeze drying protectant, prevent from significantly reducing full caprophyl caused by freeze-drying step is possible
Middle effective active protects the activity and stability of full caprophyl.
Currently preferred, the freeze-drying mode is preferably vacuum freeze drying.
In the present invention, the freeze-drying temperature is preferably -50~-53 DEG C, more preferably -52 DEG C；In the present invention,
The sublimation drying preferably controls within for 24 hours, more preferably 18~for 24 hours.In the present invention, when the freeze-drying
When mode is vacuum freeze drying, the vacuum degree is preferably 10~20Pa, more preferably 10Pa.
The present invention process of capsule is made into enteric capsule shell is not particularly limited to dispensing core material, using this field
The capsule preparation method known.
In the present invention, living bacteria count and capsule shells capacity of the amount of fill of the core material contained by core material are true
It is fixed so that living bacteria count reaches 1 × 10 in finally obtained full caprophyl complex capsule10~2.88 × 1010A/grain.
Full caprophyl complex capsule preparation method provided by the invention is simple, and operation is easy, suitable for extensive, industrial metaplasia
Production.
The present invention also provides the full caprophyl complex capsules described in preceding solution in preparing full caprophyl transplanting preparation
Application.
Specifically, the full caprophyl complex capsule provided by the invention can be combined with full caprophyl implantation technique, it can also
It is applied as sole active ingredient, can reach effective full caprophyl transplanting purpose, easy to operate, capsule free from extraneous odour, patient
Acceptance level is high.
Furthermore, it is understood that in order to improve full caprophyl transplantation effect, this hair should be administered at empty stomach in the patient for receiving full caprophyl transplanting
The full caprophyl complex capsule of bright offer；Cleaning intestinal tract is done taking the previous day it is furthermore preferred that receiving the patient of full caprophyl transplanting, with
Just full caprophyl can more effectively reach sufferer part, accelerate transplanting speed.
In order to further illustrate the present invention, technical solution provided by the invention is retouched in detail with reference to embodiment
It states, but they cannot be interpreted as limiting the scope of the present invention.
Embodiment 1
(1) material is collected：Healthy donors are selected according to the criterion of healthy donors, healthy donors are contributed in vitro new
Fresh excrement is put into feces collection bucket；
(2) bacterium solution dilutes：The in vitro fresh excretas of 100g are added in 400ml, 4 DEG C of sterile saline and are impregnated 1 minute,
It is stirred evenly with blender, about 1 minute；
(3) it filters：It is filtered successively with stainless steel mesh, strainer mesh number is incremented by 2mm, 1mm, 0.5mm, 0.25mm step by step, goes
Except excrement residue and large particulate matter, take the filtrate of final filtration to get full caprophyl filtrate；
(4) full caprophyl filtrate is subjected to eccentric cleaning：Divide 3 times
1st centrifugation：5 minutes, 2000r/min, remove supernatant, stay sediment (5ml), add physiological saline to 45ml, shake up；
2nd centrifugation：3 minutes, 2000r/min, remove supernatant, stay sediment, add physiological saline to 45ml, shake up；
3rd centrifugation：3 minutes, 2000r/min, remove supernatant, stay sediment, add physiological saline to 20ml, obtain full excrement
Bacterium, while it is 1 that 3.7g weight ratios, which are added,:1 stachyose and galactooligosaccharide, shakes up；
(5) it is freeze-dried：The mixture of full caprophyl and prebiotics is dispensed in freeze-drying bottle, 2h sizings are freezed at -20 DEG C
Afterwards, it is freezed for 24 hours under -50 DEG C of upper freeze drier, 20KPa, is prepared into core material；
(6) capsule is dispensed：Core material is fitted into small intestine enteric capsule shells in Biohazard Safety Equipment and is prepared into capsule.
The small intestine enteric capsule shells include by weight：100 parts by weight of gelatin；3~8 parts by weight of water；Alginic acid
8~15 parts by weight of sodium；8~15 parts by weight of acrylic resin；20~45 parts by weight of n-butyl acetate；Lauryl sodium sulfate 5~
25 parts by weight.Capsule shells can dissolve in the range of pH value 6~7, capsule loadings 0.15g, every full caprophyl complex capsule
Containing 2.88 × 1010A active bacteria.
The oral full caprophyl complex capsule being prepared of patient, full caprophyl complex capsule are molten under the action of small intestine intestinal juice
The positioning of full caprophyl is migrated to small intestine site by solution.
Embodiment 2
(1) material is collected：Healthy donors are selected according to the criterion of healthy donors, healthy donors are contributed in vitro new
Fresh excrement is put into special feces collection bucket；
(2) bacterium solution dilutes：The in vitro fresh excretas of 100g are added in 500ml, 4 DEG C of sterile saline and are impregnated 1 minute,
It is stirred evenly with blender, about 1 minute；
(3) it filters：It is filtered successively with stainless steel mesh, strainer mesh number is incremented by 2mm, 1mm, 0.5mm, 0.25mm step by step, goes
Except excrement residue and large particulate matter, full caprophyl suspension is collected；
(4) eccentric cleaning：Divide 2 times
1st centrifugation：5 minutes 2500 turns, remove supernatant, stay sediment (5ml), add physiological saline to 45ml, shake up；
2nd centrifugation：3 minutes 2500 turns, remove supernatant, stay sediment, add physiological saline to 20ml, obtain full caprophyl, together
When be added 3.7g Oligomeric manna sugars, shake up；
(5) it is freeze-dried：The mixture of full caprophyl and prebiotics is dispensed in freeze-drying bottle, freezes 2 hours and determines at -20 DEG C
After type, is freezed 20 hours under -53 DEG C of upper freeze drier, 20KPa, be prepared into core material；
(6) capsule is dispensed：Full caprophyl powder is fitted into colon enteric capsule shell in Biohazard Safety Equipment and is prepared into capsule,
The capsule shells system gelatin adds empty hard capsule made of auxiliary material and suitable enteric material, be positioned at ileocecus and
The capsulae enterosolubilis of colon front end disintegration drug release, can dissolve, product executes in the range of pH value 7~8《Chinese Pharmacopoeia》Standard,
Capsule loadings 0.09g, every full caprophyl capsule contain 2.88 × 1010A active bacteria.
The oral full caprophyl complex capsule being prepared of patient, full caprophyl complex capsule are molten under the action of colon intestinal juice
The positioning of full caprophyl is migrated to colon site by solution.
Comparative example 1
In addition to not adding prebiotics, other steps are same as Example 1, obtain compareing full caprophyl capsule.
Embodiment 3
The full caprophyl capsule of control prepared by comparative example 1 and full caprophyl complex capsule prepared by embodiment 1 are placed at 4 DEG C
After refrigerator preserves for 24 hours, full caprophyl type and Plantago fengdouensis in the capsule after being preserved using the detection of the bases 16s, as a result such as table 1 and table
Shown in 2.
Whether table 1 is added influence of the prebiotics to main profitable strain content in full caprophyl
| Bacterium (category) | Comparative example 1 | Embodiment 1 |
| Bifidobacterium | 4.335 | 5.153 |
| Clostridium leptum | 3.632 | 4.081 |
| Ackermam Salmonella | 0.039 | 0.047 |
| Bacillus acidi lactici | 0.014 | 0.020 |
The beneficial microbe colony content in the capsule that comparative example 1 it can be seen from 1 data of table and embodiment 1 are prepared
In normal range (NR).
Comparison discovery, the full caprophyl complex capsule caprophyl glue more complete than control prepared by comparative example 1 that the embodiment of the present invention 1 provides
The profitable strain content of capsule is significantly increased.
Content balance of the principal causative flora before and after adding specific prebiotics in the full caprophyl of 2. healthy donors of table
| Bacterium (category) | Comparative example 1 | Embodiment 1 |
| Clostridium | 0.585 | 0.54 |
| Haemophilus | 0.058 | 0.049 |
| Thermophilic courage bacterium | 0.012 | 0 |
| Klebsiella | 0 | 0 |
| Acinetobacter calcoaceticus | 0 | 0 |
| Helicobacter | 0 | 0 |
| Salmonella | 0 | 0 |
| Shigella | 0 | 0 |
From the data in table 2, it can be seen that pathogenic flora content is in normal range (NR) in the capsule that comparative example 1 and embodiment 1 provide.
Through it was found that, in the full caprophyl capsule of control prepared by comparative example 1, the content of principal causative flora is higher than the preparation of embodiment 1
Full caprophyl complex capsule.
The result of comprehensive Tables 1 and 2, which can be seen that the present invention, can effectively adjust full caprophyl using prebiotics as core material
Bacterial community significantly improves profitable strain content and reduces pernicious bacteria content, keeps Bacterial community more reasonable, the full excrement after transplanting
Bacterium function and effect are more notable.
Embodiment 4
The function and effect of full caprophyl complex capsule are verified in this experiment.
(1) intervene object：Body mass index (BMI) >=28, Food intolerance detection at least exist a kind or a kind or more intolerant to
By the obese people of food, totally 15；
(2) healthy donors：The last week is carried according to preset dietary reference table to be adjusted healthy donors diet, is kept away
Exempt to take in high sugared, high in fat and irritable food, eat fruits and vegetables more and is rich in dietary fiber food；
(3) full caprophyl complex capsule is prepared according to example 1；
(4) intervene object and intervene first day oral 30 full caprophyl transplanting bladder compound, it is before intervening and dry
Prognosis is measured on the 30th day using 16S technologies compares its every index situation of change, including：
Food intolerance type and rank, abdominal pain scoring, the daily defecation frequency, irritable bowel syndrome (IBS) scale score,
Manifest anxiety scale (SAS) scoring, Depression Scale (SDS) scoring and patients before and after intervention receptor (obesity) Intestinal flora constitute type
And content Plantago fengdouensis situation.
Test result：
As shown in Figure 1, obese people takes the scoring of the abdominal pain before and after full caprophyl complex capsule provided by the invention, daily row
The food species quantity of bowel frequency number and 2 grades of Food intolerances has a significant decrease (p ＜ 0.01), 1 grade of Food intolerance and 3 grades
The food species quantity of Food intolerance also reduces accordingly.
As shown in Fig. 2, obese people takes the IBS-SSS scale scores before and after full caprophyl complex capsule provided by the invention
It significantly reduces (p ＜ 0.01), shows that full caprophyl complex capsule provided by the invention can significantly improve the disease of irritable bowel syndrome
Shape.
As shown in figure 3, obese people takes the anxiety SAS scorings and suppression before and after full caprophyl complex capsule provided by the invention
Strongly fragrant SDS scorings have significant decrease (p ＜ 0.01), show that full caprophyl complex capsule provided by the invention can significantly improve obesity
The mental health state of crowd.
As shown in figure 4, after obese people takes full caprophyl complex capsule provided by the invention, in section's categorization levels,
Cud Cordycepps (Ruminococcaceae.) abundance significantly rises, p<0.01, and reach unanimity with healthy donors；According to document report
Road, cud Cordycepps can promote SCFAs to generate, so as to improve the metabolism of host's glucose and energy.Show that the present invention carries
The full caprophyl complex capsule supplied can effectively adjust obese people intestinal microflora.
In conclusion full caprophyl complex capsule provided by the invention can effectively be transplanted to disease affected part after taking
It is strong to be effectively improved the Food intolerance of patient, abdominal pain, diarrhea, irritable bowel syndrome, psychology for position, and fast onset therapeutic effect
The symptoms such as health situation.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also answered
It is considered as protection scope of the present invention.
Claims (10)
1. a kind of full caprophyl complex capsule, including wall material and core material, the wall material is enteric capsule shell, and the core material includes full excrement
Bacterium and prebiotics；Living bacteria count in the full caprophyl complex capsule is 1 × 1010~2.88 × 1010A/grain.
2. full caprophyl complex capsule according to claim 1, which is characterized in that the enteric capsule shell is selected from small intestine enteric
Capsule shells or colon enteric capsule shell.
3. full caprophyl complex capsule according to claim 1, which is characterized in that the mass ratio of the full caprophyl and prebiotics
It is 5~10:2~5.
4. full caprophyl complex capsule according to claim 1, which is characterized in that the preparation method of the full caprophyl include with
Lower step：
(1) excrement is impregnated with 3~5 DEG C of sterile saline, is filtered after stirring, collection liquid phase component is filtrate of dejecta；
(2) filtrate of dejecta for obtaining step (1) is centrifuged with the rotating speed of 1500~3000r/min, takes precipitation and sterile physiological salt
Water mixes, and obtains full caprophyl.
5. full caprophyl complex capsule according to claim 4, which is characterized in that in step (1), the filtering uses successively
The strainer filtering of aperture 2mm, 1mm, 0.5mm and 0.25mm.
6. full caprophyl complex capsule according to claim 4 or 5, which is characterized in that in the step (1), stool quality
And the ratio of sterile saline volume is 1g:300~800ml；
In step (2), the ratio of the precipitation quality and sterile saline volume is 1:5~15.
7. full caprophyl complex capsule according to claim 1, which is characterized in that the prebiotics include stachyose, oligomeric
It is one or more in galactolipin Oligomeric manna sugar and xylo-oligosaccharide.
8. the preparation method of full caprophyl complex capsule, includes the following steps described in claim 1~7 any one：
Full caprophyl and prebiotics are mixed, freeze-drying obtains core material；Core material is distributed into enteric capsule shell, full excrement is obtained
Bacterium complex capsule.
9. the preparation method of full caprophyl complex capsule according to claim 8, which is characterized in that the condition of the freeze-drying
For：Temperature -50~-53 DEG C are freeze-dried, sublimation drying is within for 24 hours.
10. application of the full caprophyl complex capsule described in claim 1~7 any one in preparing full caprophyl transplanting preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810865338.1A CN108567799A (en) | 2018-08-01 | 2018-08-01 | A kind of full caprophyl complex capsule and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810865338.1A CN108567799A (en) | 2018-08-01 | 2018-08-01 | A kind of full caprophyl complex capsule and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108567799A true CN108567799A (en) | 2018-09-25 |
Family
ID=63571904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810865338.1A Pending CN108567799A (en) | 2018-08-01 | 2018-08-01 | A kind of full caprophyl complex capsule and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108567799A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109125357A (en) * | 2018-10-24 | 2019-01-04 | 南京益恒寿生命科技有限公司 | A kind of probiotics that treating intestinal irritable syndrome-caprophyl liquid complex liquid |
| CN109394795A (en) * | 2018-10-23 | 2019-03-01 | 上海市第十人民医院 | A kind of intestines bacterium capsule preparation method thereof and intestines bacterium capsule |
| CN110575459A (en) * | 2019-09-16 | 2019-12-17 | 广东南芯医疗科技有限公司 | preparation method of coprophilous fungi transplanting capsule |
| CN110638782A (en) * | 2019-09-16 | 2020-01-03 | 广东南芯医疗科技有限公司 | Method for preparing capsule |
| WO2020212297A1 (en) * | 2019-04-15 | 2020-10-22 | Institut D'investigacions Biomèdiques August Pi I Sunyer (Idibaps) | Long-term stable live fecal microbiota composition |
| CN112458019A (en) * | 2020-12-02 | 2021-03-09 | 广东南芯医疗科技有限公司 | Fecal bacteria liquid and preparation method and application of freeze-dried powder of fecal bacteria liquid |
| CN113209039A (en) * | 2021-04-22 | 2021-08-06 | 重庆晶云生物科技有限公司 | Enterobacter capsule and preparation method thereof |
| CN114042090A (en) * | 2021-11-17 | 2022-02-15 | 宁波大学医学院附属医院 | Intestinal flora capsule and preparation method thereof |
| CN115177642A (en) * | 2022-08-05 | 2022-10-14 | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | Composition for regulating ulcerative colitis intestinal flora and preparation method and application thereof |
| CN115305223A (en) * | 2022-06-17 | 2022-11-08 | 东源益康(北京)医药科技有限公司 | Enterobacter composition with effect of preventing and treating autism and preparation method and application thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1545936A (en) * | 2003-12-01 | 2004-11-17 | 上海交大昂立股份有限公司 | Edible combination containing active Lactobacillus paracasei and preparation method thereof |
| CN103124559A (en) * | 2010-08-04 | 2013-05-29 | 托马斯·朱利叶斯·波洛迪 | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| CN104522648A (en) * | 2014-12-18 | 2015-04-22 | 杭州龙达新科生物制药有限公司 | Tetragenus probiotic preparation and application thereof |
| CN104922158A (en) * | 2015-06-05 | 2015-09-23 | 中国人民解放军第三军医大学第三附属医院 | Fecal microbiota capsule, as well as preparation method and application thereof |
| CN105120847A (en) * | 2013-03-14 | 2015-12-02 | 塞拉拜姆有限责任公司 | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| CN105193856A (en) * | 2015-09-25 | 2015-12-30 | 南昌大学 | Application of transplantation of artificially-cultured fecal floras in treatment of intestinal diseases |
| CN106689672A (en) * | 2017-01-04 | 2017-05-24 | 陈雨 | Synbiotics composition, synbiotics preparation, preparation method and application thereof |
| CN107308190A (en) * | 2017-07-04 | 2017-11-03 | 宇萃达生物科技（苏州）有限公司 | Adjust the probiotic composition and its culture, preparation, purposes of human body microecological balance |
| CN108064132A (en) * | 2014-10-31 | 2018-05-22 | 霍勒拜欧姆公司 | The method and composition related with the antimicrobial treatments of illness and diagnosis |
-
2018
- 2018-08-01 CN CN201810865338.1A patent/CN108567799A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1545936A (en) * | 2003-12-01 | 2004-11-17 | 上海交大昂立股份有限公司 | Edible combination containing active Lactobacillus paracasei and preparation method thereof |
| CN103124559A (en) * | 2010-08-04 | 2013-05-29 | 托马斯·朱利叶斯·波洛迪 | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| CN105120847A (en) * | 2013-03-14 | 2015-12-02 | 塞拉拜姆有限责任公司 | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| CN108064132A (en) * | 2014-10-31 | 2018-05-22 | 霍勒拜欧姆公司 | The method and composition related with the antimicrobial treatments of illness and diagnosis |
| CN104522648A (en) * | 2014-12-18 | 2015-04-22 | 杭州龙达新科生物制药有限公司 | Tetragenus probiotic preparation and application thereof |
| CN104922158A (en) * | 2015-06-05 | 2015-09-23 | 中国人民解放军第三军医大学第三附属医院 | Fecal microbiota capsule, as well as preparation method and application thereof |
| CN105193856A (en) * | 2015-09-25 | 2015-12-30 | 南昌大学 | Application of transplantation of artificially-cultured fecal floras in treatment of intestinal diseases |
| CN106689672A (en) * | 2017-01-04 | 2017-05-24 | 陈雨 | Synbiotics composition, synbiotics preparation, preparation method and application thereof |
| CN107308190A (en) * | 2017-07-04 | 2017-11-03 | 宇萃达生物科技（苏州）有限公司 | Adjust the probiotic composition and its culture, preparation, purposes of human body microecological balance |
Non-Patent Citations (1)
| Title |
|---|
| 潘春梅: "《微生态制剂生产及应用》", 30 September 2014 * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109394795A (en) * | 2018-10-23 | 2019-03-01 | 上海市第十人民医院 | A kind of intestines bacterium capsule preparation method thereof and intestines bacterium capsule |
| CN109125357A (en) * | 2018-10-24 | 2019-01-04 | 南京益恒寿生命科技有限公司 | A kind of probiotics that treating intestinal irritable syndrome-caprophyl liquid complex liquid |
| WO2020212297A1 (en) * | 2019-04-15 | 2020-10-22 | Institut D'investigacions Biomèdiques August Pi I Sunyer (Idibaps) | Long-term stable live fecal microbiota composition |
| CN110575459A (en) * | 2019-09-16 | 2019-12-17 | 广东南芯医疗科技有限公司 | preparation method of coprophilous fungi transplanting capsule |
| CN110638782A (en) * | 2019-09-16 | 2020-01-03 | 广东南芯医疗科技有限公司 | Method for preparing capsule |
| CN112458019A (en) * | 2020-12-02 | 2021-03-09 | 广东南芯医疗科技有限公司 | Fecal bacteria liquid and preparation method and application of freeze-dried powder of fecal bacteria liquid |
| CN113209039A (en) * | 2021-04-22 | 2021-08-06 | 重庆晶云生物科技有限公司 | Enterobacter capsule and preparation method thereof |
| CN114042090A (en) * | 2021-11-17 | 2022-02-15 | 宁波大学医学院附属医院 | Intestinal flora capsule and preparation method thereof |
| CN115305223A (en) * | 2022-06-17 | 2022-11-08 | 东源益康(北京)医药科技有限公司 | Enterobacter composition with effect of preventing and treating autism and preparation method and application thereof |
| CN115305223B (en) * | 2022-06-17 | 2024-01-23 | 东源益康(北京)医药科技有限公司 | Enterobacter composition with effect of preventing and treating autism as well as preparation method and application thereof |
| CN115177642A (en) * | 2022-08-05 | 2022-10-14 | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | Composition for regulating ulcerative colitis intestinal flora and preparation method and application thereof |
| CN115177642B (en) * | 2022-08-05 | 2023-05-30 | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | Composition for regulating intestinal flora of ulcerative colitis and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108567799A (en) | A kind of full caprophyl complex capsule and its preparation method and application | |
| Lee et al. | Gut microbiota and obesity: An opportunity to alter obesity through faecal microbiota transplant (FMT) | |
| CN104922158B (en) | Caprophyl capsule and its preparation and application | |
| US9737577B2 (en) | Lactic acid bacterium-containing preparation | |
| CN110150669B (en) | Probiotic composition suitable for diabetic patients and application thereof | |
| KR20170118828A (en) | Therapeutic and prophylactic compositions produced by intestinal microbial populations | |
| CN110093286B (en) | Bifidobacterium pseudocatenulatum CCFM1046, composition thereof, fermented food, application, microbial inoculum and preparation method of microbial inoculum | |
| CN108850397A (en) | A kind of probiotic gel candy and preparation method thereof of only diarrhea | |
| CN110106103B (en) | Bifidobacterium pseudocatenulatum CCFM1047, composition thereof, fermented food, application, microbial inoculum and preparation method of microbial inoculum | |
| CN111996153A (en) | Bifidobacterium breve and application thereof | |
| CN114558036A (en) | Application of bacteroides fragilis in improvement and treatment of diarrhea | |
| CN113249280A (en) | Streptococcus thermophilus STN26, bacterium powder and application in uric acid reducing product | |
| CN108938675A (en) | A kind of caprophyl positioning transplantation method | |
| CN109394795A (en) | A kind of intestines bacterium capsule preparation method thereof and intestines bacterium capsule | |
| CN114681493B (en) | Application of bifidobacterium animalis subspecies lactis | |
| CN110801016A (en) | Prebiotics polypeptide composite probiotics for relaxing bowel and promoting digestion and absorption and preparation method thereof | |
| CN101336938B (en) | Use of probiotics in preparing composition for treating and preventing hand-foot-mouth disease | |
| CN113598374A (en) | Application of lactobacillus plantarum in weight loss | |
| CN109486732A (en) | A kind of bifidobacterium longum and its application | |
| CN116121154A (en) | Leuconostoc lactis and application thereof | |
| CN116549494A (en) | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof | |
| CN108653298B (en) | Monosaccharide composition, pharmaceutical preparation and application thereof | |
| CN101297820A (en) | Streptococcus faecium function signal molecule formulation and product thereof for reducing fat and slimming | |
| WO2021134740A1 (en) | Tibetan pig fecal microbiota capsule for relieving diarrhea in weaned piglet, and preparation method therefor | |
| CN105343132B (en) | Composition, the drug and preparation method thereof for treating colitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180925 |